香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 有關完成增資豐瑞氟業 茲提 述 復星 國 際有 限公 司 （「本公司 」） 於 2025 年 8 月 17 日 刊 發之 公 告（「 該 公 告 」），內容有關 海南礦業簽訂增資協議 以增資豐瑞氟業 。除文義另有所指 外，本公告所界定的詞彙與該等公告所使用者具有相同涵義。 董事會欣然宣佈， 增資協議項 下 載明的所有先決條件 均 已獲滿足或 獲 書面豁 免，本次增資於 2025 年 8 月 29 日交割。 交 割後 ， 本公司透過海南礦業間接 持有目標公司 15.7895%的股權。 承董事會命 最新進展公告 須予披露交易 董事長 郭廣昌 2025 年 8 月 29 日 於本公告日期，本公司之執行董事為郭廣昌先生、汪群斌先生、陳啟宇先生、徐曉亮先生、 龔平先生、黃震先生及潘東輝先生；非執行董事為李樹培先生、李富華先生及羅元澧先生； 而獨立非執行董事為章晟曼先生、張化橋先生、張彤先生、李開復博士及曾璟璇女士 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願公告 關於菜鳥智慧物流網絡有限公司之 爭議解決 本公告乃復星國際有限公司（「 本公司 」，連同其附屬公司統稱「本集團 」） 自願刊發。 本公司股東及潛在投資者於買賣本公司之證券時務請審慎行事。 茲提述本公司 分別於 2025 年 3 月 28 日及 2025 年 3 月 30 日刊發之盈利警告 公告（「盈利警告公告 」）及截至 2024 年 12 月 31 日止年度 之 業績公告， 以 及 於 2025 年 4 月 25 日刊發之 本公司 年報。除文義另有所指外，本公告所使用 之詞彙與盈利警告公告所界定者具有相同涵義。 本公司 董事 會 （「董事會 」）謹 此 通知 本 公司 之 股東 及 潛在 投資 者 ，於 2025 年 8 月 29 日 ，Stater Investment Holdings Limited（「SIHL」）（ 本公 司 之全 資 附屬 公 司 ） 與 菜 鳥 智 慧 物 流 網 ...

Core Viewpoint - Fosun International's Chairman Guo Guangchang emphasized the company's commitment to increasing investments in the biopharmaceutical sector, aiming to deepen its focus on advantageous industries and capture global market leadership [1]. Group 1: Business Performance - In the first half of the year, Fosun achieved significant breakthroughs across multiple business segments, particularly in the biopharmaceutical sector [1]. - The company is poised to leverage growth opportunities through technological innovation to achieve breakthrough advancements [1]. Group 2: Innovation Drug Development - Fosun has a pipeline of innovative drug candidates with a potential global market size ranging from $5 billion to $10 billion [1]. - In addition to its subsidiary, Fuhong Hanlin, Fosun is advancing its CAR-T technology platform and other innovative drug developments, which present substantial growth potential [1]. Group 3: Strategic Approach - Guo highlighted the importance of both licensing in and licensing out for innovative drugs, indicating a strategic approach to not rush into licensing agreements, even if they may yield high prices [1]. - The company aims to build its global capabilities in research and development, clinical trials, and sales within the biopharmaceutical field, which is seen as a fundamental pathway for Fosun to evolve into a global pharmaceutical giant [1].

Core Viewpoint - Fosun International is committed to increasing investments in the biopharmaceutical sector, focusing on leveraging its strengths to capture global market opportunities [1] Group 1: Business Strategy - Fosun has achieved significant breakthroughs in multiple business segments in the first half of the year, particularly in the biopharmaceutical sector, and aims to drive growth through technological innovation [1] - The company has a pipeline of innovative drugs with a potential global market size of $5 billion to $10 billion, including products from its subsidiaries such as Fosun Pharma and its CAR-T technology platform [1][2] Group 2: Innovation and R&D - Fosun emphasizes the importance of both licensing in and licensing out for innovative drugs, aiming to develop products into globally competitive offerings rather than rushing to license them out [2] - The company believes that cancer treatment will not rely on a single method but will involve a combination of drugs, devices, and multi-molecular therapies, positioning itself uniquely in this area [2] Group 3: Long-term Vision - Fosun's leadership highlights that building a competitive enterprise requires a long-term commitment, as seen in the 15-year journey of its subsidiary, Fosun Pharma, which has seen substantial investment with delayed returns [3] - The company intends to focus on its established industries, innovating within traditional sectors, such as the recent development of a new low-alcohol product in the liquor industry to cater to health-conscious consumers [3]

Core Viewpoint - Fosun Tourism Group reported steady growth in its performance for the six months ending June 30, 2025, with adjusted net profit increasing by over 40% year-on-year [2]. Financial Performance - In the first half of 2025, Fosun Tourism's tourism operations revenue reached RMB 10.23 billion, a 1.6% increase compared to the same period in 2024 [2]. - Total revenue for the company was RMB 9.53 billion, marking a 1.3% year-on-year growth, achieving a historical high [2]. - Operating profit was RMB 1.27 billion, up 22.4% year-on-year [2]. - Adjusted EBITDA reached RMB 2.40 billion, reflecting a 15.8% increase [2]. - Adjusted net profit was RMB 460 million, showing a 42.0% year-on-year growth [2]. Market Context - The Chinese cultural and tourism market saw 3.285 billion trips taken, with total tourism spending exceeding RMB 3.15 trillion, setting a recent record [2]. - The industry is entering a new growth phase driven by increased travel willingness and the release of cultural tourism demand [2]. Club Med Performance - Club Med's global revenue reached RMB 9.25 billion in the first half of 2025, a 3.8% increase year-on-year [3]. - The average daily room rate increased by 5.1% to RMB 2,021, indicating strong brand premium [3]. - Operating profit for Club Med was RMB 1.27 billion, up 11.0% year-on-year [3]. Domestic Operations - Atlantis Sanya maintained high revenue at RMB 760 million, with an average occupancy rate of 88.4% and approximately 3.08 million visitors [6]. - The resort saw a 71% year-on-year increase in overseas guest numbers due to enhanced marketing efforts [6]. - The Taicang Alps International Resort achieved RMB 100 million in revenue, receiving 400,000 visitors [6]. Future Outlook - Strong demand for summer vacations and the upcoming winter season is expected to sustain booking growth in the second half of 2025 and the first half of 2026 [4]. - The company plans to enhance global operational capabilities and accelerate product innovation and iteration [7]. - A new AI initiative, "AI G.O," is set to launch in September 2025, aimed at optimizing customer vacation experiences and improving operational efficiency [7].

Financial Data and Key Metrics Changes - The total revenue for the first half of 2025 reached RMB87.3 billion, slightly down from the same period last year, with overseas revenue increasing from 43% to 53% of total revenue [3][4] - Industrial operating profit remained stable at RMB3.15 billion, with profit attributable to the owner of the parent at RMB0.66 billion [3] - Adjusted NAV reached HKD18 per share, reflecting continuous improvement [4] - Cash and cash equivalents reached RMB67.83 billion, with a decrease in the average cost of borrowing from 5.6% to 5.3% [5][6] Business Line Data and Key Metrics Changes - The Health segment recorded RMB22.57 billion in total revenues, with net profit to parents increasing by 48.3% year on year [22] - Fosun Pharma's revenue was RMB19.43 billion, with innovative drug revenue rising by 14% year on year [25][26] - The Wealth segment's total revenue was RMB27.83 billion, up by 3.3% year on year, primarily driven by growth in insurance revenue [39] - The Intelligent Manufacturing segment recorded RMB4 billion in revenue, a decrease of 24.6% year on year, primarily due to the consolidation scope [42] Market Data and Key Metrics Changes - Overseas revenue for Fosun Pharma accounted for 38.1% of total revenue, with a year-on-year increase of 2.1 bps [23] - The tourism business, particularly Club Med, reported a record high revenue during the reporting period, operating in 40 countries and regions [34][51] - Yiren's jewelry and fashion segment showed signs of recovery in Q2, with revenue rebounding to RMB7.61 billion [35] Company Strategy and Development Direction - The company aims to create a global happiness ecosystem focusing on health, happiness, and wealth [46] - Strategic focus includes business streamlining, transitioning to asset-light operations, and enhancing technological innovation [48][49] - The company is committed to globalization, with overseas revenue accounting for 53% of total revenue [49] - The flywheel model is being implemented, connecting insurance capital with investment and industrial operations [52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of the consumption sector and the potential for innovative drugs [64] - The company is focusing on existing sectors where it has established strengths rather than entering new sectors [68] - There is a strong emphasis on technological advancements, particularly in AI and gene development, to drive future innovation [67] Other Important Information - The company has been recognized for its strong ESG performance, aiming for peak carbon emissions by 2028 and carbon neutrality by 2050 [58][60] - Significant investments have been made in R&D, with Fosun Pharma's expenditures reaching RMB2.58 billion [24] Q&A Session Summary Question: What sectors will the company focus on in the second half? - Management highlighted confidence in the recovery of the consumption sector and breakthroughs in innovative drugs, emphasizing potential in their pipeline [64] Question: How does the company view its innovation strategy? - The company aims to build its own global R&D capabilities and is focused on licensing in and out, with a long-term vision to become a major player in the pharmaceutical market [66] Question: What is the company's approach to new sectors? - Management stated that the focus will remain on sectors where the company has established strengths, rather than pursuing new sectors without a solid foundation [68]

Financial Data and Key Metrics Changes - In the first half of 2025, the total revenue reached RMB87.3 billion, slightly down from the same period last year, with overseas revenue increasing from 43% to 53% of total revenue [3][4] - The industrial operating profit remained stable at RMB3.15 billion, and profit attributable to the owner of the parent was RMB0.66 billion [3] - The adjusted NAV reached HKD18 per share, reflecting continuous improvement [4] - Cash and cash equivalents reached RMB67.83 billion, remaining stable compared to last year, with a decrease in the average cost of borrowing from 5.6% to 5.3% [5][6] Business Line Data and Key Metrics Changes - The Health segment recorded RMB22.57 billion in total revenues, with net profit to parents increasing by 48.3% year on year, driven by growth in Fosun Pharma's profit [22] - Fosun Pharma's revenue was RMB19.43 billion, with innovative drug revenue rising by 14% year on year [24][25] - The Wealth segment's total revenue was RMB27.83 billion, up by 3.3% year on year, primarily driven by growth in insurance revenue [38] - The Intelligent Manufacturing segment recorded RMB4 billion in revenue, a decrease of 24.6% year on year, primarily due to the consolidation scope [41] Market Data and Key Metrics Changes - Overseas revenue accounted for 53% of total revenue, indicating a significant shift towards global operations [49] - Club Med reported record high revenue during the reporting period, with international visitors increasing by 71% year on year [54] - The tourism business saw improvements, with occupancy rates reaching 99% and sales volume increasing by 55% year on year [36] Company Strategy and Development Direction - The company aims to create a global happiness ecosystem focusing on health, happiness, and wealth [46] - Strategic focus includes business streamlining, transitioning to asset-light operations, and enhancing technological innovation [48] - The company is committed to globalization, with a significant increase in overseas revenue and partnerships with international capital [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of the consumption sector and the potential for innovative drugs [65] - The company is focusing on existing sectors where it has established strengths rather than entering new sectors [70] - There is a strong belief in the potential of the pharmaceutical pipeline, with products expected to have significant market potential [66] Other Important Information - The company has been recognized for its strong ESG performance, aiming for peak carbon emissions by 2028 and carbon neutrality by 2050 [59][61] - The company is actively reducing debt levels and divesting non-core assets, generating cash inflow of over RMB8 billion [12] Q&A Session Summary Question: What sectors will the company focus on in the second half? - The company will continue to focus on the recovery in the consumption sector and innovations in drugs, expressing confidence in future growth [65] Question: What is the company's strategy regarding innovative drugs? - The company aims to build its own global R&D and sales capabilities while being patient with its pipeline products, which have significant potential [66][67] Question: How does the company view technological advancements? - The company sees great potential in combining advancements in gene development and AI for future innovations [68]

Financial Highlights - Total revenue reached RMB 873 billion, down by 108% year-on-year, mainly impacted by Yuyuan revenue declining[8] - Overseas revenue accounted for 53% of total revenue, up by 7 percentage points year-on-year, reaching RMB 4667 billion[8] - Industrial operating profit slightly increased to RMB 315 billion, excluding the impact of Happiness Business[8] - Investment in Technology and Innovation was RMB 636 billion, with a stable share of total revenue at 73%[8] - Adjusted NAV was HKD 180 per share, totaling HKD 258 billion[8] - Public markets financing reached RMB 1362 billion, excluding consolidated subsidiaries[14] Business Segment Performance - Health segment revenue was RMB 2257 billion[50] - Happiness segment revenue was RMB 3372 billion, a decrease of 219% year-on-year[10, 95] - Intelligent Manufacturing segment revenue was RMB 402 billion[143] - Wealth segment revenue was RMB 2783 billion, up by 33% year-on-year[10, 134] Strategic Development and Globalization - Fosun Insurance Portugal's international business recorded premiums of EUR 924 million, nearly 30% of total[21] - Henlius' overseas product profits grew over 200% year-on-year[26] - Shede Spirits' overseas sales exceeded RMB 10 million, up by 35% year-on-year[26]

Core Viewpoint - Fosun International is leveraging macroeconomic trends and industry dynamics to drive steady growth through innovation and global operations, achieving total revenue of 87.28 billion RMB and a net profit of 6.6 billion RMB in the first half of 2025 [1] Group 1: Financial Performance - Total revenue reached 87.28 billion RMB, with operating profit at 3.15 billion RMB and net profit attributable to shareholders at 660 million RMB [1] - The company maintains a healthy debt-to-capital ratio of 53%, with strong cash reserves [1] - Standard & Poor's affirmed a "stable" outlook for the company's credit rating in May 2025 [1] Group 2: Globalization Strategy - Over 50% of Fosun's revenue comes from international operations, with overseas income at 46.67 billion RMB, marking a significant step in its globalization efforts [2] - The company operates in over 40 countries and regions, showcasing its ability to navigate complex global trade environments [2] Group 3: Innovation and R&D - Fosun's R&D investment reached 3.6 billion RMB in the first half of 2025, focusing on creating a competitive product portfolio across various sectors [7] - The company has established over 20 global innovation centers, enhancing its technological capabilities [7] - Significant breakthroughs in pharmaceuticals include the global sales of innovative drugs, with sales from the anti-PD-1 drug reaching 597.7 million RMB [4] Group 4: Market Expansion - Fosun is actively expanding into emerging markets, including strategic partnerships in Saudi Arabia for healthcare and electric vehicle solutions [5] - The company is enhancing its presence in traditional markets while also exploring new opportunities in regions like the Middle East and Asia [5] Group 5: AI and Technology Integration - Fosun is implementing an "embrace AI" strategy to enhance operational efficiency and product innovation across its sectors [10] - The company has developed an AI-driven decision-making platform in the pharmaceutical sector, improving data accuracy and operational efficiency [10] Group 6: Future Outlook - The combination of globalization and innovation is expected to drive significant growth for Fosun, with a clear trajectory for long-term value creation [11] - The company is positioned to capitalize on global opportunities, supported by a robust financial foundation and innovative capabilities across multiple sectors [11]

Core Viewpoint - Fosun International is leveraging macroeconomic trends and industry dynamics to drive steady growth through innovation and global operations, achieving total revenue of 87.28 billion RMB in the first half of 2025, with a net profit of 660 million RMB [1] Group 1: Financial Performance - Total revenue reached 87.28 billion RMB, with operational profit at 3.15 billion RMB and net profit at 660 million RMB [1] - The debt-to-capital ratio remained healthy at 53%, indicating a stable financial condition [1] - Standard & Poor's affirmed a "stable" outlook for the company's credit rating in May 2025 [1] Group 2: Globalization Strategy - Fosun's overseas revenue amounted to 46.67 billion RMB, accounting for 53% of total revenue, reflecting a deepened global operational phase [2] - The company operates in over 40 countries and regions, showcasing its robust cross-cycle operational capabilities [2] Group 3: Market Expansion and Innovation - Fosun Portugal Insurance has expanded into emerging markets like Brazil and Angola, with international business accounting for 28.2% of total operations [3] - Club Med achieved record global performance with revenue of 9.25 billion RMB, a 3.8% increase year-on-year, and operating profit of 1.27 billion RMB, an 11% increase [3] Group 4: Pharmaceutical Innovations - Fosun Pharma's subsidiary, Fuhong Hanlin, achieved global sales of 597.7 million RMB for its PD-1 monoclonal antibody, with approvals in multiple countries [4] - The company reported a 200% increase in overseas product profits, with cash inflows from business development contracts exceeding 1 billion RMB, a 280% year-on-year growth [4] Group 5: Strategic Collaborations - Fosun Pharma is collaborating with Fakeeh Care Group in Saudi Arabia to promote innovative treatment products [5] - The company is also partnering with Khaled Juffali Company to provide production line solutions for the electric vehicle industry in Saudi Arabia [5] Group 6: Technological Innovation - Fosun invested 3.6 billion RMB in R&D in the first half of 2025, focusing on creating a competitive product portfolio across various strategic sectors [7] - The company has established over 20 global innovation centers, enhancing its technological capabilities [7] Group 7: AI Integration - Fosun is implementing an "embrace AI" strategy to enhance operational efficiency and product innovation across its sectors [10] - The Pharm AID platform in the pharmaceutical sector improves decision-making efficiency by 50% [10] Group 8: Future Outlook - The company is positioned for sustainable growth with a strong financial foundation and innovative momentum across multiple sectors, including pharmaceuticals, consumer goods, and tourism [11] - The dual strategy of "globalization + innovation" is expected to drive future growth and value creation [11]